Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Drug Profile

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Alternative Names: AFM 12; AFM 18; AFM 20; AFM 21; AFM 22; AFM 24; AFM 24+; AFM 26; AFM 26+; AMV-564; anti CD19 x anti CD16; anti CD33 X anti CD3; anti-EGFRvIII/CD16A Tand AB; anti-EGFRvIII/CD3 TandAb; anti-EpCAM TandAb; Antibody-based non-Hodgkin's lymphoma therapeutics - Affimed; MHC-peptide complex antibody - Affimed; T-564; Trispecific Abs

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Amphivena Therapeutics
  • Class Bispecific antibodies; Monoclonal antibodies; Trispecific antibodies
  • Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; CD19 antigen modulators; CD200 antigen modulators; CD3 antigen modulators; CD33 antigen modulators; Epidermal growth factor receptor antagonists; Epithelial cell adhesion molecule inhibitors; Fc gamma receptor IIIA modulators; Immunomodulators; Major histocompatibility complex inhibitors; Natural killer cell stimulants; T lymphocyte stimulants; T-lymphocyte differentiation antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 05 Apr 2017 Adverse events and pharmacodynamics data from a preclinical studies in Cancer presented at the (108th Annual meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Mar 2017 Preclinical data for AFM 24 and AFM 26 in Cancer released by Affimed
  • 11 Jan 2017 Preclinical trials in Head and neck cancer, Lung cancer and Colorectal cancer in Germany (Parenteral) (Affimed Therapeutics pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top